Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00838916 · ClinicalTrials.gov registry record · Phase 3
A Study to Determine the Safety and Efficacy of Albiglutide in Patients With Type 2 Diabetes
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 779
- Enrollment target
NCT00838916: Completed Phase 3 study, sponsored by GlaxoSmithKline.
NCT00838916 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 779 participants, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00838916, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 779 participants
- Enrollment target
Study Summary
A study to determine the safety and efficacy of albiglutide in subjects with type 2 diabetes.
Primary Outcome
HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over a 2- to 3-month period. The BL HbA1c value is defined as the last non-missing value before the start of treatment. Change from BL was calculated as the value at Week 52 minus the value at BL. Based on analysis of covariance (ANCOVA): change = treatment + BL HbA1c + prior myocardial infarction history + age category + region + current antidiabetic therapy. Difference of least squares
Interventions
- DRUG insulin glargine
- BIOLOGICAL albiglutide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 779 participants |
| Start Date | 2009-02 |
| Est. Completion | 2013-05 |
| Phase | Phase 3 |
What the finished NCT00838916 record still lists
NCT00838916 is an interventional study that assigns participants to a tested intervention. The registered 779 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target.
The record links to 0 conditions, and to 2 interventions - of which insulin glargine is the first listed.
NCT00838916 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00838916 about?
NCT00838916 is a clinical study titled "A Study to Determine the Safety and Efficacy of Albiglutide in Patients With Type 2 Diabetes". A study to determine the safety and efficacy of albiglutide in subjects with type 2 diabetes.
What is the current status of trial NCT00838916?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 779 participants. The study started on 2009-02. Estimated completion is 2013-05.
What interventions are being tested in trial NCT00838916?
The interventions under investigation include: insulin glargine (DRUG), albiglutide (BIOLOGICAL).
Who is sponsoring clinical trial NCT00838916?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00838916's enrollment target sits among peer trials
779 438th of 2000 higher than 1,563 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05046613 · 780 participants
Observational Study to Assess Maternal, Fetal and Infant Outcomes Following Exposure to Rimegepant
- NCT05100862 · 780 participants · Phase 3
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
- NCT05513872 · 780 participants · Phase 1
Overcoming Nicotine Dependence to Enable Quitting
- NCT06310031 · 780 participants · NA
Investigation of the BrioVAD System for the Treatment of Left Ventricular Heart Failure
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia